Vertex Pharmaceuticals: Now That’s an Approval!

Shares of Vertex Pharmaceuticals (VRTX) are soaring after the FDA approved its cystic-fibrosis drug. UBS analyst Matthew Roden says the decision should help push Vertex “towards profitability.” He explains why: De-risking makes Vertex shares more broadly ownable: The FDA’s approval of Orkambi at a price of $259,000 suggests NPV upside without any further label expansions required, [...]